These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 17548134)

  • 1. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria.
    Cai QL; Wei F; Lin YH; Shao DD; Wang H
    Vaccine; 2004 Nov; 23(2):267-77. PubMed ID: 15531046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
    Teo WH; Nurul AA; Norazmi MN
    Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies.
    Fox BA; Xing-Li P; Suzue K; Horii T; Bzik DJ
    Exp Parasitol; 1997 Feb; 85(2):121-34. PubMed ID: 9030663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies and reactive T cells against the malaria heat-shock protein Pf72/Hsp70-1 and derived peptides in individuals continuously exposed to Plasmodium falciparum.
    Behr C; Sarthou JL; Rogier C; Trape JF; Dat MH; Michel JC; Aribot G; Dieye A; Claverie JM; Druihle P
    J Immunol; 1992 Nov; 149(10):3321-30. PubMed ID: 1431109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant multi-epitope, multi-stage malaria vaccine candidate expressed in Escherichia coli.
    Li M; Bi H; Dong W; Xu W; Li Q; Li Y
    Chin Med J (Engl); 1999 Aug; 112(8):691-7. PubMed ID: 11601273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.
    Calvo-Calle JM; Hammer J; Sinigaglia F; Clavijo P; Moya-Castro ZR; Nardin EH
    J Immunol; 1997 Aug; 159(3):1362-73. PubMed ID: 9233633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
    Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential antibody responses to Plasmodium falciparum-derived B-cell epitopes induced by diepitope multiple antigen peptides (MAP) containing different T-cell epitopes.
    Vasconcelos NM; Siddique AB; Ahlborg N; Berzins K
    Vaccine; 2004 Dec; 23(3):343-52. PubMed ID: 15530679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem use of PCR and synthetic peptides to map helper T-cell epitopes on 27-kDa sexual stage antigen of Plasmodium falciparum.
    Koski GK; Ploton IN; Viscidi R; Kumar N
    Pept Res; 1996; 9(3):127-35. PubMed ID: 8875592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
    BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
    Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice.
    Jiang Y; Lin C; Yin B; He X; Mao Y; Dong M; Xu P; Zhang L; Liu B; Wang H
    Chin Med J (Engl); 1999 Aug; 112(8):686-90. PubMed ID: 11601272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.